65--NOI - DNA Sequencing of Bone Marrow Failure Syndro
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
NATIONAL INSTITUTES OF HEALTH OLAO
Contract Value
Not provided
Codes & Classification
Solicitation Number
75N98027Q00027
NAICS
325413 - In-Vitro Diagnostic Substance Manufacturing
Classification Code
6550
Additional Details
Documents2
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, has issued a combined synopsis/solicitation for the procurement of custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. This procurement is intended to support ongoing DNA sequencing efforts related to bone marrow failure syndromes, specifically within the NHLBI Hematology Branch. The primary objective is to acquire proprietary sequencing kits that enable error-correcting sequencing (ECS), which is critical for maintaining scientific continuity and ensuring compatibility with the laboratory’s established bioinformatics pipeline.
This requirement is being pursued as a non-competitive action under FAR 12.603 and FAR 6.302-3(a)(2)(ii), as Integrated DNA Technologies, Inc. (IDT) is the sole owner, manufacturer, and distributor of the ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry. The NHLBI Hematology Branch has utilized this specific chemistry since 2019, and its continued use is necessary to prevent technical batch effects across longitudinal patient cohorts and to maintain the integrity of ongoing research. The procurement will be executed as a firm-fixed-price purchase order and is not expected to exceed the simplified acquisition threshold.
The solicitation is issued under NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing), with a small business size standard of 1,250 employees. However, this opportunity is not set aside for small businesses. The applicable Product Service Code is 6550. All responsible sources are invited to submit capability statements, proposals, or quotations, which will be considered by the agency, although the intent is to negotiate directly with IDT due to the proprietary nature of the required kits.
The contracting entity for this procurement is the NIH Office of Logistics and Acquisition Operations (OLAO), a federal office within the Department of Health and Human Services. The primary point of contact for this notice is Nicholas S. Capobianco, who can be reached via email at [email protected].
Interested parties should note that the solicitation and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective March 13, 2026. The notice remains active, with a response deadline of May 11, 2026. Additional details and attachments related to this opportunity can be accessed through the official SAM.gov listing at https://sam.gov/opp/f50457338b334262b0f95018f2b586e6/view.
Contractors evaluating this opportunity should consider the specialized and proprietary nature of the required deliverables, the non-competitive procurement approach, and the necessity for compatibility with existing laboratory protocols and bioinformatics infrastructure. These elements are expected to remain constant throughout the contract lifecycle.